Ergomed, a U.K.-based drug development and services company, has appointed Rolf Stahel to its board as non-executive chairman.
Rolf Stahel brings over 30 years' experience in the global pharmaceutical industry. He led Shire Pharmaceuticals Group as CEO from 1994 to 2003, and during his tenure implemented six mergers and acquisitions.
Rolf Stahel worked with Wellcome in Switzerland, Italy, Thailand, Singapore and the U.K. As regional director, based in Singapore, Rolf was responsible for 18 Pacific Rim countries. His last position with Wellcome was director of Group Marketing, based in the U.K., covering Group Strategy, R&D portfolio evaluation, marketing of existing and new products and business development. In this position, Rolf reported to the chief executive of Wellcome. Rolf joined Shire Pharmaceuticals Group in March 1994 as its chief executive.
Rolf sits on the Advisory Board of Imperial Business School (Imperial College London). He has been non-executive chairman of several companies, including Newron Pharmaceuticals, Cosmo Pharmaceuticals, PowderMed and EUSA Pharma. He is currently non-executive chairman of Connexios Life Sciences and Midatech.